Serina Therapeutics, Inc. announced the appointment of Dr. Simba Gill as Executive Chairman. Serina?s proprietary POZ PlatformTM aims to develop and improve therapeutics across multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Simba brings to Serina a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key roles at Maxygen, Systemix, Boehringer Mannheim and Celltech.

He earned his MBA at INSEAD and received his Ph.D. from King?s College, London. Dr. Gill will play a pivotal role in guiding Serina through its next phase of growth and development, leveraging his expertise to drive strategic expansion initiatives.